Why is Nifty Bank the hot topic in recent times?
Why is Nifty Bank the hot topic in recent times?

Why is Nifty Bank the hot topic in recent times?

Next week will be a decisive week as the monthly contracts will expire and high volatility is expected.

DSIJ Intelligence Article rating: 3.7

Next week will be a decisive week as the monthly contracts will expire and high volatility is expected. We suggest you to watch out for these crucial levels as Nifty Bank shows no signs of reversal.  

Whats in for Nifty next week? Find out here!
Whats in for Nifty next week? Find out here!

Whats in for Nifty next week? Find out here!

Next week will be a decisive week as the monthly contracts will expire and high volatility is expected.

DSIJ Intelligence Article rating: 3.5

Next week will be a decisive week as the monthly contracts will expire and high volatility is expected.

Top Nifty 500 stocks with golden crossover
Top Nifty 500 stocks with golden crossover

Top Nifty 500 stocks with golden crossover

Want to check long-term trend action? Nothing better than looking for a Golden Crossover. In this article, we have listed the top Nifty 500 stocks with golden crossover.

DSIJ Intelligence Article rating: 2.9

Want to check long-term trend action? Nothing better than looking for a Golden Crossover. In this article, we have listed the top Nifty 500 stocks with golden crossover.

Stock below Rs 100: This micro-cap stock reported almost three-fold rise in net profit!
Stock below Rs 100: This micro-cap stock reported almost three-fold rise in net profit!

Stock below Rs 100: This micro-cap stock reported almost three-fold rise in net profit!

This exhibits a trend of sustained and improved profitability along with an operational turnaround of the business. 

DSIJ Intelligence Article rating: 4.4

This continuous trend of growing profitability is very evident in the third consecutive quarter, where the net profit grew by 190 per cent QoQ all the way to Rs 58 lakh from Rs 20 lakh

Zydus Cadila gets approval to market unique cancer drug in the US
Zydus Cadila gets approval to market unique cancer drug in the US

Zydus Cadila gets approval to market unique cancer drug in the US

Zydus is the 'first approved applicant' for Nelarabine Injection which had annual sales of approximately US$ 34.5 million in the United States.

DSIJ Intelligence Article rating: 5.0

Zydus Cadila has received final approval from the USFDA to market Nelarabine Injection 250MG/50ML in the United States. Zydus Pharmaceuticals USA Inc (Zydus) was granted a Competitive Generic Therapy (CGT) designation for Nelarabine Injection, Single-Dose Vial. 

These smallcap and midcap stocks staged a smart recovery from days low!
These smallcap and midcap stocks staged a smart recovery from days low!

These smallcap and midcap stocks staged a smart recovery from days low!

Recovery from the lower levels indicates that the market participants actively participated in these stocks at the lower levels:

DSIJ Intelligence Article rating: 3.1

Recovery from the lower levels indicates that the market participants actively participated in these stocks at the lower levels.

Overnight Digest: Watch out for these stocks on Monday, November 22!
Overnight Digest: Watch out for these stocks on Monday, November 22!

Overnight Digest: Watch out for these stocks on Monday, November 22!

DSIJ Intelligence Article rating: 3.6

The shares of Escorts gained by more than 19 per cent on Thursday with a spurt in volume of over 6 times. A huge breakout was seen in the share price of Escorts as Kubota announced that it will to increase its stakes in Escorts.

RSS
First21842185218621872189219121922193Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR